AbbVie

4Q Revenues: $15.1 billion (+6%)

4Q Loss: $22 million (earnings were $822 million 4Q23)

FY Revenues: $56.3 billion (+4%)

FY Earnings: $4.3 billion (-12%)

Comments: Global immunology portfolio sales in the quarter were $7.3 billion, up 5%. Humira sales were $1.7 billion, down 49%. Skyrizi sales were $3.8 billion, up 58% and Rinvoq sales were $1.8 billion, up 46%.

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.
 

Global sales from the neuroscience portfolio were $2.5 billion, up 20%. Botox Therapeutic sales were $873 million, up 12.5%. Vraylar sales were $924 million, up 17%. Ubrelvy sales were $303 million, up 30%. Qulipta sales were $201 million, up 76%.

Global revenues from the aesthetics portfolio were $1.3 billion, down 5%. Botox Cosmetic sales were $687 million, down 4%. Juvederm sales were $279 million, down 16%.

Results in the quarter include a charge of $3.5 billion related to the emraclidine intangible asset acquired as part of the Cerevel Therapeutics acquisition and an acquired IPR&D and milestones expense of $1.6 billion.